Supernus Pharmaceuticals, Inc. (SUPN) Q2 2018 Earnings Results

Supernus Pharmaceuticals Beats on EPS, Stock Up 0.66%

Supernus Pharmaceuticals reported a strong EPS performance, beating expectations by 17.5%. However, the lack of revenue data leaves some uncertainty. The stock reacted positively, rising 0.66%, likely driven by the better-than-expected earnings per share. Investors may be encouraged by management's focus on growth and product development.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.57	N/A	+17.50%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management remains cautiously optimistic about the company's direction. They emphasized the importance of continued growth and product development.

Management expressed satisfaction with the EPS performance despite not providing revenue figures.

They highlighted ongoing efforts to enhance product offerings and market presence.

Supernus Pharmaceuticals Beats on EPS, Stock Up 0.66%

Key numbers

Management commentary

Supernus Pharmaceuticals, Inc.

More earnings this week

Supernus Pharmaceuticals Beats on EPS, Stock Up 0.66%

Key numbers

Management commentary